05:57:57 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-29 Kvartalsrapport 2024-Q2
2024-05-16 X-dag ordinarie utdelning BRAINP 0.00 DKK
2024-05-15 Årsstämma 2024
2024-05-07 Bokslutskommuniké 2023
2023-10-11 Extra Bolagsstämma 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-30 X-dag ordinarie utdelning BRAINP 0.00 DKK
2023-05-26 Årsstämma 2023
2023-04-28 Bokslutskommuniké 2022
2022-09-29 Kvartalsrapport 2022-Q2
2022-09-02 Extra Bolagsstämma 2022
2022-05-19 X-dag ordinarie utdelning BRAINP 0.00 DKK
2022-05-18 Årsstämma 2022
2022-04-29 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriVård & Omsorg
Brain+ är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling för behandling av demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa. Brain+ har sitt huvudkontor i Köpenhamn.
2023-10-24 14:40:14
  • The Brain+ series TO 2 warrant exercise and directed share issue have been registered with the Danish Business Authority (Danish: Erhvervsstyrelsen)
  • Interim shares (Danish: IA/midlertidig aktie) from the warrant exercise will be converted into common Brain+ shares (ISIN DK0061670205) and, following conversion, together with shares from the directed issue commence trading on Nasdaq First North Copenhagen on 30 October 2023

Copenhagen, Denmark, 24 October2023 - Brain+ A/S (Nasdaq First North: BRAINP)

Last week, Brain+ A/S ("Brain+" or "the Company") announced the outcome of the exercise period of its warrants of series TO 2 (the "Warrants"), which were issued in connection with the Company's unit rights issue in May 2023. In connection with the Warrant exercise, the Company also carried out a directed issue to guarantors of the Warrant exercise (the "Directed Issue"). The Warrant exercise and the Directed Issue has now been registered with the Danish Business Authority.

After the completion and registration of the Warrant exercise and the Directed Issue with the Danish Business Authority, the number of shares in Brain+ has increased by 21,199,564 shares, from 44,262,866 to 65,462,430 shares, and the Company's nominal share capital has increased by DKK 2,119,956.40, from DKK 4,426,286.60 to DKK 6,546,243.00.

The conversion from interim shares issued based on the Warrant exercise to common shares in Brain+ with the permanent ISIN DK0061670205, will be made on 31 October 2023. Application has been made to Nasdaq Copenhagen A/S for the new shares in the permanent ISIN to be admitted to trading on Nasdaq First North Growth Market Denmark. It is expected that the first day of trading of the new shares will be on 30 October 2023.

Advisors
In connection with the unit rights issue including the issue and exercise of warrants of series TO 2, Sedermera Corporate Finance AB and Gemstone Capital A/S act as financial advisors to Brain+. Markets & Corporate Law Nordic AB act as legal advisor. Nordic Issuing AB is the issuing agent.

For more information about the warrant exercise, please contact:

Sedermera Corporate Finance AB
Phone: +46 (0) 40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se

Gemstone Capital A/S
Phone: +45 33 22 07 00

E-mail: sh@gemstonecapital.com

www.gemstonecapital.com 

For more information about Brain+, please contact:

Kim Baden-Kristensen, CEO
Phone: +45 31 39 33 17
E-mail: kim@brain-plus.com

www.brain-plus.com

Certified Adviser

Keswick Global AG

Phone: +43 1 740 408 045

E-mail: info@keswickglobal.com